1. Introduction {#sec1-jpm-10-00041}
===============

Approximately 22,440 newly diagnosed cases of ovarian cancer and 14,080 deaths occurred in the United States in 2017 \[[@B1-jpm-10-00041]\]. Only 10% of ovarian cancers are non-epithelial malignant ovarian germ cell tumors (MOGCTs) and sex cord-stromal cell tumors (SCSTs) (5% each). Epithelial ovarian cancer (EOC) differs in epidemiology, etiology, and treatment. Patients diagnosed with EOC should be tested for hereditary susceptibility genes \[[@B2-jpm-10-00041]\]. Beyond germline pathogenic variants (gPVs) in breast cancer genes 1 and 2 (*BRCA1/2*), alterations in *BRIP1*, *RAD51C*, and *RAD51D* and mismatch repair (MMR) genes also enhance EOC risk. Next-generation sequencing (NGS)-based mutation panels profile multiple genes simultaneously, allowing the reporting of numerous genes while saving labor and resources. The identification of homologous recombination (HR)-deficient EOC has significant clinical implications related to the therapeutic choices of either chemotherapeutic or targeted agents. Indeed, patients with *BRCA* mutations or HR deficiency may be treated with maintenance poly (ADP-ribose) polymerase (PARP) inhibitors in first-line settings or at recurrence. Currently, olaparib, rucaparib, and niraparib have been approved by the Food and Drug Administration (FDA) and/or European Medicines Agency (EMA) for the treatment of EOC \[[@B3-jpm-10-00041]\]. Furthermore, aurora kinases (AURKs) are serine/threonine kinases essential for the onset and progression of mitosis and seem to be promising prognostic factors for EOC among other cancers. AURKs have been shown to interact with DNA repair mechanisms and other cell cycle regulators, and could be novel therapeutic targets. Metformin has anti-angiogenic activity in vivo and chemosensitizing effects in vitro in ovarian cancer; nevertheless, epidemiological studies on its use in ovarian cancer are not equally promising as compared with preclinical evidence. The prevalence of ovarian cancer in women with endometriosis is higher than sporadic ovarian cancer. Endometriosis is frequently described in association with ovarian clear cell carcinoma (OCCC) and endometrioid ovarian carcinoma (EnOC). Epigenetics may be implicated in the pathogenesis of endometriosis, whereas DNA methylation serves as an epigenetic biomarker for EOC. Unlike EOC, MOGCTs typically occur in the first three decades of life. Surgery and platinum-based chemotherapy remain the standard of care. Even in advanced-stage disease, patients have a high chance to be cured. MOGCTs rarely develop genetic mutations. The aim of this article is to provide a comprehensive overview of the genetic and therapeutic evolution of EOC and MOGCTs.

2. Genomic Profiling of EOC by NGS {#sec2-jpm-10-00041}
==================================

Recently, microarray technologies have been used to elucidate the complexity of genomic alterations of EOC. NGS technology has become widely available to determine a patient's precise genetic profiling and identify novel mutations for new drug targets. In this context, patients with EOC with *BRCA* mutations or HR deficiency experience therapeutic benefit from platinum agents and PARP inhibitors, whereas immune checkpoint inhibitors are effective in tumors with microsatellite instability \[[@B4-jpm-10-00041],[@B5-jpm-10-00041]\]. Furthermore, the costs to test multiple genes in a pan-cancer panel are lower as compared to sequencing isolated genes sequentially \[[@B6-jpm-10-00041]\].

Importantly, multigene panels decrease the chances of missing out on a pathogenic mutation. When a limited number of genes are tested based on clinical indication and results are negative, targetable mutations in untested genes cannot be fully excluded. This risk is even higher in cases of moderate-penetrance genes for which clinical phenotype is less clear, as well as in those without typical presentation or relevant family history \[[@B7-jpm-10-00041]\].

HR is crucial for carcinogenesis. Single-strand DNA breaks (SSBs) are normally repaired by MMR, base excision repair, and nucleotide excision repair, in which PARP1/2 have a key role \[[@B8-jpm-10-00041]\]. Inhibition of these proteins leads to single-strand break accumulation and, consequently to double-strand DNA breaks (DSBs) and cytotoxicity. Unlike PARP2, PARP1 can also mediate the repair of DSBs and regulates the rate of DNA replication fork progression in replication stress \[[@B9-jpm-10-00041]\]. DSBs are repaired either through HR or through non-homologous end joining (NHEJ)---the choice of which is determined by cell cycle phase and chromatin context \[[@B10-jpm-10-00041]\]. NHEJ is the preferred mechanism for repair of DSBs in G1 when a DNA template that could be used for HR is absent.

HR deficiency can be assessed by the presence of germline and somatic mutations in HR genes using tumor sequencing. However, if mutations in susceptibility genes are ruled out by tumor sequencing, no additional test is required \[[@B11-jpm-10-00041]\]. Furthermore, HR deficiency leads to the occurrence of genomic scars, represented by the loss of heterozygosity (LOH), large-scale state transitions (LSTs), and telomeric allele imbalance (TAI). Two commercial genomic scar assays identify tumors with HR deficiency. "Myriad's myChoice HRD assay tests for the presence of LOH, TAI, and LSTs across the genome \[[@B12-jpm-10-00041]\]". A tumor with an HRD score of 42 and above is labeled as HRD positive. The "FoundationFocus™ CDx *BRCA* LOH" detects mutations in the *BRCA1/2* and the percentage of the genome affected by LOH in DNA from tumor tissue samples \[[@B13-jpm-10-00041]\]. Tumors are considered LOH-high if the score is 16 and above.

In addition to mutations in the *BRCA1/2* genes, genomic alterations involving other genes in HR pathways have been recognized, including Fanconi anemia genes (*BRIP1*, *PALB2*), the core RAD genes (*RAD51C*, *RAD51D*), and genes involved in HR pathways either directly (*CHEK2*, *BARD1*, *NBN*, *ATM*) or indirectly (*cyclin-dependent kinase (CDK) 12*) \[[@B4-jpm-10-00041]\]. However, their real effect over assessment of EOC risk is still uncertain. Genome-wide association studies identified single-nucleotide polymorphisms associated with susceptibility for EOC. The 27 loci associated with invasive EOC identified so far account for 6.4% of the polygenic risk for EOC \[[@B14-jpm-10-00041]\].

*RAD51C* loss-of-function gPVs are rare among EOC patients, with their prevalence varying between 0.3% and 1.1% \[[@B15-jpm-10-00041]\]. The lifetime risk of EOC among *RAD51C* carriers is approximately 5% \[[@B15-jpm-10-00041]\]. Both *RAD51C* and *RAD51D* are EOC susceptibility genes that are characterized by a reduced magnitude when compared to *BRCA1/2*. The increased EOC risk for *RAD51C* and *RAD51D* supports their addition to criteria for risk-reducing salpingo-oophorectomy \[[@B16-jpm-10-00041]\]. Furthermore, genetic defects in these genes can function as biomarkers for PARP sensitivity.

Clinical testing for *PALB2* in EOC is not currently recommended. The majority of studies reported relative risks that ranged from 0.9 to 5.5 and lacked statistical power \[[@B17-jpm-10-00041]\]. A study analyzing data from 524 families with *PALB2* gPVs from 21 countries reported that the estimated risk of EOC at age 80 years was 5% (95% CI, 2--10%) \[[@B18-jpm-10-00041]\]. For *PALB2* carriers, risk-reducing surgery should be recommended for cases with strong family history of EOC. The predictive value of *PALB2* is supported by the evidence that *PALB2*-associated tumors respond to platinum-based chemotherapy and PARP inhibitors \[[@B4-jpm-10-00041]\].

Several gPVs in the so-called moderate- and low-penetrance genes, such as *BRIP1*, have been reported to be correlated with a moderate lifetime risk of EOC. The prevalence of *BRIP1* gPVs among familial EOC patients can reach 0.7% \[[@B19-jpm-10-00041]\]. The cumulative lifetime risk of EOC diagnosis among *BRIP* mutants has been estimated as 5--5.8% \[[@B17-jpm-10-00041]\], predominantly following menopause. The elevated risk of EOC diagnosis justifies the recommendation for risk-reducing oophorectomies among asymptomatic carriers and this should be guided based on family history and individual's preference.

Other hereditary cancer syndromes are also associated with EOC. A lack of *MSH2*, substantial mutations in the *MLH1* or *MSH2* genes, *MLH1*-methylation inactivation, and transcriptional silencing lead to Lynch syndrome \[[@B20-jpm-10-00041]\]. MMR deficiency has been demonstrated in 20--40% of endometrial cancers \[[@B21-jpm-10-00041],[@B22-jpm-10-00041]\], but data on its prognostic value are controversial \[[@B21-jpm-10-00041],[@B23-jpm-10-00041],[@B24-jpm-10-00041]\]. [Table 1](#jpm-10-00041-t001){ref-type="table"} reports the frequency and EOC risk of well-established moderate- and high-penetrance susceptibility genes for EOC, whereas [Table 2](#jpm-10-00041-t002){ref-type="table"} depicts clinical trials of PARP inhibitors in EOC and their therapeutic potential in patients with HR deficiency.

Overall, for EOC patients, guidelines recommend testing for moderate- or high-penetrance *BRCA1/2*, *RAD51C*, *RAD51D*, *BRIP1*, and mismatch repair genes. Cascade testing should be offered to relatives of carriers of gPVs. Gene sequencing can provide results with different biological meanings. A genetic alteration can be pathogenic or likely pathogenic, benign or likely benign, or finally of uncertain significance. The latter represents the main challenge when interpreting genetic alterations. In a large retrospective cohort of individuals who had genetics testing, 7.7% of unique gPVs of uncertain significance were reclassified. The majority of them (91.2%) were considered benign or likely benign \[[@B25-jpm-10-00041]\]. Similarly, in a study on reinterpretation of BRCA1/2 gPVs of uncertain significance, 93.7% of the reclassified variants were benign or likely benign \[[@B26-jpm-10-00041]\]. Despite this, gPVs of uncertain significance can be a great source of distress for patients and their families.

Although less prevalent, some non-epithelial ovarian cancers also have their risk enhanced by genetic factors. *DICER1* syndrome, characterized by germline truncating *DICER1* mutations includes predisposition to pleuropulmonary blastoma and Sertoli--Leydig cell tumors \[[@B27-jpm-10-00041]\]. Germline mutations in *STK11* cause Peutz--Jeghers syndrome and are also associated with SCSTs \[[@B28-jpm-10-00041]\].

3. Clinical Development of PARP Inhibitors {#sec3-jpm-10-00041}
==========================================

PARP inhibitors were originally developed for cancer treatment as radio- and chemosensitizing drugs. In 2014, the EMA approved a capsule formulation of olaparib as maintenance treatment in platinum-sensitive, *BRCA*-mutated (germline and/or somatic), high-grade serous EOC (stydy 19, NCT00753545) \[[@B29-jpm-10-00041]\]. A few months later, the FDA approved olaparib capsules for the treatment of patients with deleterious or suspected deleterious germline *BRCA*-mutated advanced EOC, who have been treated with three or more prior lines of chemotherapy (stydy 42, NCT01078662) \[[@B30-jpm-10-00041]\]. A tablet formulation of olaparib with improved bioavailability has been developed to facilitate olaparib administration to patients. It was approved by both agencies for the maintenance therapy of platinum-sensitive recurrent EOC regardless of *BRCA* mutational status (SOLO-2, NCT01874353) \[[@B29-jpm-10-00041],[@B31-jpm-10-00041]\]. FDA approval of olaparib maintenance treatment in 2018 was supported by the SOLO-1 trial (NCT01844986), examining the efficacy of olaparib vs. placebo in patients with *BRCA*-mutated advanced EOC who responded to first-line platinum-based chemotherapy \[[@B32-jpm-10-00041]\].

Rucaparib was approved by the FDA in 2016 and by the EMA in 2018 for patients with deleterious *BRCA* mutation (germline and/or somatic)-associated EOC who have been treated with two or more lines of chemotherapy. The efficacy was supported by a pooled analysis of two single-arm clinical trials: study 10 (NCT01482715) and ARIEL 2 (NCT01891344) \[[@B33-jpm-10-00041],[@B34-jpm-10-00041],[@B35-jpm-10-00041]\]. ARIEL 2 enrolled platinum-sensitive EOC patients, assigned to one of three HR deficiency categories assessed on the most recent collected tumor sample: *BRCA1/2* mutated, *BRCA* wild-type (*BRCA*wt) with LOH high, and *BRCA*wt with LOH low, respectively \[[@B32-jpm-10-00041],[@B34-jpm-10-00041]\]. The median progression-free survival (PFS) was significantly longer in the BRCA-mutated subgroup (12.8 months; HR = 0.27, *p* \< 0.0001) and in the *BRCA*wt/LOH high (5.7 months; HR = 0.62, *p* = 0.011), as compared to the *BRCA*wt/LOH low subgroup (5.2 months). Similarly, the objective response rate was higher in the *BRCA*1/2 mutated and *BRCA*wt/LOH high subgroups, than the *BRCA*wt/LOH low subgroup (80%, 29%, and 10%, respectively). Genomic LOH was shown to be a better predictor of response to rucaparib in patients with *BRCA*wt tumors with a sensitivity of 78%, compared to mutations in other HR deficiency genes (sensitivity 11%, *p* \< 0.0001) or methylation of *BRCA1* or *RAD51C* (sensitivity 48%, *p* \< 0.021). However, by combining mutations in HR deficiency genes and methylation of *BRCA1* or *RAD51C*, no statistically different sensitivity was observed (sensitivity 59%, *p* = 0.13).

In March 2017, the FDA approved niraparib as maintenance treatment of recurrent EOC in responders to platinum-based chemotherapy (NOVA trial, NCT01847274) \[[@B36-jpm-10-00041]\]. Equally, in November 2017, the EMA approved niraparib for the maintenance treatment of patients with platinum-sensitive relapsed high-grade serous EOC who responded to platinum-based chemotherapy. In October 2019, the FDA approved niraparib for patients with advanced HR-deficient EOC treated with at least three prior chemotherapy regimens based on the results of the Quadra trial (NCT02354586) \[[@B37-jpm-10-00041]\].

Apart from the already approved PARP inhibitors for the treatment of EOC in different settings, veliparib and talazoparib are in earlier clinical development \[[@B38-jpm-10-00041],[@B39-jpm-10-00041]\]. Veliparib was evaluated mainly combined with chemotherapy or targeted agents, whilst at least in vitro talazoparib demonstrates more potent anti-tumor activity based on its enhanced PARP-DNA trapping ability.

Although PARP inhibitors oppose the catalytic activity of PARP in general, there are remarkable differences in their abilities to trap PARP based on the size and structure of each separate molecule \[[@B40-jpm-10-00041]\]. This results in significant differences in doses among PARP inhibitors. It has been demonstrated that PARP trapping is associated with PARP inhibitor cytotoxic activity.

Recently, combination therapy of PARP and immune checkpoint inhibitors is being developed based on the immuno-regulatory effects of PARP inhibition. MEDIOLA (NCT02734004) is a phase II study of olaparib and durvalumab in patients with relapsed, platinum-sensitive, BRCA-mutated EOC, which reported an overall response rate of 72% \[[@B41-jpm-10-00041]\]. The phase I/II TOPACIO study (NCT02657889) investigated the combination of niraparib and pembrolizumab in patients with platinum resistant/refractory EOC \[[@B42-jpm-10-00041]\]. The overall response and the disease control rates were 18% and 65%, respectively. There was no difference in response by *BRCA* and HR deficiency status.

4. AURKs in Ovarian Cancer {#sec4-jpm-10-00041}
==========================

AURKs are serin-threonine kinases, which act as molecular switches, regulating multiple processes in cell division including spindle organization, chromosome alignment, the spindle assembly checkpoint, cytokinesis, and the abscission checkpoint \[[@B43-jpm-10-00041]\]. The family of AURKs includes *aurora kinase A* (*AURKA*, STK15), *aurora kinase B* (*AURKB*, STK12), and *aurora kinase C* (*AURKC*, STK13) \[[@B43-jpm-10-00041],[@B44-jpm-10-00041]\]. AURKs contain an N-terminal domain (39--139 aa), a kinase domain (250--300 aa), and a C-terminal domain (15--20 aa) \[[@B45-jpm-10-00041]\]. *AURK* overexpression is common in EOC and has been correlated with prognostic value.

There is enough evidence of cross-talk between AURKs and *p53*. Furthermore, AURKA interacts with proteins involved in apoptosis, specifically *p73*, a protein of the family of *p*53, implicated in the regulation of cell cycle and apoptosis. An in vitro study demonstrated that inhibition of *AURKA* in a *p53*-deficient cell line results in the expression of genes associated with *p73*-mediated apoptosis \[[@B46-jpm-10-00041]\].

DNA damage induces activation of checkpoint kinase 1 (*CHEK1*), which then transduces the checkpoint signal and facilitates cell cycle arrest and DNA damage repair. It has been described as a synergistic anti-tumoral effect between AURKA and CHEK1 inhibitors in EOC \[[@B47-jpm-10-00041]\]. Expression of *AURKA* and *CHEK1* has been associated with dismal prognosis in early-stage EOC. Based on that, molecular analyses of the pathways in which these genes participate may be used to select patients for whom AURKA inhibitors would be effective.

Within the context of AURK inhibition in EOC, a large cohort of 240 patients with recurrent high-grade EOC who were referred to the phase I clinical trials program has been analyzed retrospectively \[[@B48-jpm-10-00041]\]. Targeted agents included bevacizumab, vascular endothelial growth factor (VEGF) receptor inhibitors, and other compounds targeting the PI3K/AKT/mTOR, MAPK, Src, Wee1, and AURKA signaling pathways. Chemotherapy plus bevacizumab-based or AURKA kinase inhibitor-based regimens were potentially effective and yielded a median PFS of more than 6 months, which is indicative of potential benefit deriving from AURKA inhibitors. A preclinical study in EOC cell lines demonstrated that the selective small inhibitor alisertib inhibits epithelial--mesenchymal transition via the PI3K/AKT/mTOR and sirtuin-1 mediated pathways \[[@B49-jpm-10-00041]\]. The selectivity in the inhibition of *AURKA* may be related to a more favorable toxicity profile and a better therapeutic index than pan-AURK inhibitors.

In vitro inhibition of *AURKA* with alisertib decreased the expression of PARP and *BRCA1/2* and stimulated the NHEJ repair pathway \[[@B50-jpm-10-00041]\]. Following these findings, in vivo studies confirmed that AURKA inhibition elevated phosphorylated DNA-PKcs and decreased PARP levels. Alisertib treatment alone or combined with paclitaxel significantly reduced the growth and dissemination of orthotopic EOC xenografts. The potent synergy between alisertib and paclitaxel in vitro suggests that the combination of these agents may be more effective than either drug alone \[[@B51-jpm-10-00041]\].

ENMD-2076 has selective activity against *AURKA*, as well as kinases involved in angiogenesis \[[@B52-jpm-10-00041]\]. The rationale for a phase II trial of ENMD-2076 in OCCC was that apart from the strong expression of *VEGF* in this histological subtype, the overexpression of *AURKA* had also been associated with chemoresistance \[[@B53-jpm-10-00041],[@B54-jpm-10-00041]\].

The pan-AURK inhibitor danusertib hydrochloride shows a dominant AURKB kinase inhibition-related cellular phenotype and mechanism of action in cells in vitro and in vivo. In a phase I trial, 56 patients received escalating doses of danusertib (24 h infusion every 14 days) without granulocyte colony-stimulating factor (G-CSF). Among them, one patient with refractory EOC had 27% tumor regression and 30% biochemical response, suggesting a potential activity in this setting \[[@B55-jpm-10-00041]\].

Finally, the pan-AURK inhibitor tozasertib not only causes cytokinesis defects through AURK inhibition but is also a potent inhibitor of necroptosis, a cell death process regulated and executed by the RIPK1, RIPK3, and MLKL signaling axis. Tozasertib may enhance carboplatin activity by MTT proliferative assay in both platinum-sensitive and platinum-resistant EOC cell lines, regardless of p53 status \[[@B56-jpm-10-00041]\]. A low dose of tozasertib promotes paclitaxel-induced apoptosis and is effective in paclitaxel-resistant cells \[[@B57-jpm-10-00041]\]. Furthermore, the combination of tozasertib with valproic acid led to a synergistic effect on gynecologic cancer cells \[[@B58-jpm-10-00041]\].

5. Metformin and Ovarian Cancer {#sec5-jpm-10-00041}
===============================

Metformin was officially introduced to diabetes treatment in 1957 and still represents a well-recognized therapeutic choice for type 2 diabetes \[[@B59-jpm-10-00041]\]. The preclinical anti-cancer efficacy of metformin has been demonstrated mainly in breast cancer \[[@B60-jpm-10-00041]\]. In vitro studies have demonstrated that metformin may stimulate AMP-activated protein kinase activation in breast cancer cells, with inhibition of the mTOR pathway \[[@B61-jpm-10-00041]\]. In this regard, several inhibitors of the PI3K/Akt pathway are under investigation in animal models and clinical trials in the field of breast cancer \[[@B62-jpm-10-00041],[@B63-jpm-10-00041]\].

Similarly, metformin inhibits the AMPK-dependent growth of multiple EOC cell lines and inhibits several receptor tyrosine kinases, such as human epidermal growth factor receptor 4 (HER4), epidermal growth factor receptor (EGFR), and platelet-derived growth factor receptor (PDGF-R) \[[@B64-jpm-10-00041]\]. Treatment with metformin in vitro and in vivo in murine experiments resulted in decreased angiogenesis in metastatic tissues and attenuated ovarian cancer cell adhesion \[[@B65-jpm-10-00041],[@B66-jpm-10-00041]\]. It has also been demonstrated that the reduction in neovascularization following metformin treatment can be driven by blockage of the mTOR signaling pathway \[[@B67-jpm-10-00041],[@B68-jpm-10-00041]\]. Furthermore, metformin targets ALDH+ EOC stem cell populations in vitro, leading to suppressed angiogenesis, proliferation, and tumor growth \[[@B69-jpm-10-00041]\].

Programmed cell death is mediated by several protein factors that include the Bcl-2 protein family and the caspase group of cysteine proteases. The upregulation of the Bax (Bcl-2 family member) increases the activity of the caspases and enhances the apoptotic activity. The inhibition of caspase-3 is included in the mechanism by which insulin promotes apoptosis. Apart from Bax, insulin downregulates Bad, which prevents programmed cell death. Many preclinical EOC studies correlate Bcl-2-regulated apoptosis to metformin's chemosensitizing effects \[[@B65-jpm-10-00041],[@B70-jpm-10-00041],[@B71-jpm-10-00041]\]. The chemosensitizing effect of metformin seems to be correlated with p53 function. In the presence of *p53*, metformin suppresses hexokinase II (glycolytic enzyme) and pyruvate dehydrogenase kinase (anti-apoptotic serine/threonine kinase) \[[@B72-jpm-10-00041]\]. As a result, EOC cells are sensitized to metformin. Furthermore, metformin may re-sensitize platinum- or paclitaxel-resistant EOC cells to chemosensitive cells, either by induction of autophagy or via its anti-inflammatory properties \[[@B67-jpm-10-00041],[@B73-jpm-10-00041]\].

While metformin has wide anti-cancer effects in preclinical models, results of studies evaluated the association between metformin use and survival in ovarian cancer patients with type 2 diabetes are inconclusive \[[@B74-jpm-10-00041],[@B75-jpm-10-00041],[@B76-jpm-10-00041],[@B77-jpm-10-00041],[@B78-jpm-10-00041]\]. So far, sufficient evidence verifying metformin use in ovarian cancer prevention is lacking. Register-based epidemiological studies of the incidence of ovarian cancer in patients taking metformin are depicted in [Table 3](#jpm-10-00041-t003){ref-type="table"}.

6. Endometriosis and Ovarian Cancer Risk {#sec6-jpm-10-00041}
========================================

Both endometriosis and ovarian cancer have certain pathogenic similarities, and share similar risk factors \[[@B82-jpm-10-00041]\]. The prevalence of ovarian cancer that appears in patients with endometriosis is greater than sporadic ovarian cancer in the general population. Women with endometriosis have an increased risk for certain subtypes of EOC, such as OCCC and EnOC \[[@B83-jpm-10-00041],[@B84-jpm-10-00041]\].

There is strong evidence of a genetic link between endometriosis and ovarian cancer. Mutations in *ARID1A* have been found in several cancers, and SWI/SNF-associated gene mutations occur in approximately 20% of all malignancies, whereas the most frequent mutations in *ARID1A* are found in OCCC (46--57%) and EnOC (approx. 30%) \[[@B85-jpm-10-00041],[@B86-jpm-10-00041],[@B87-jpm-10-00041],[@B88-jpm-10-00041]\]. Mutations in *ARID1A* result in the loss of BRG-associated factor 250a (BAF250a), a protein with an important role in cell proliferation and tumor suppression. It has been shown that loss of BAF250a presumably occurs at an early stage in carcinogenesis, as has been observed in a subset of benign endometriotic cysts of the ovary and deep-infiltrating endometriosis. Samartzis et al. described a complete loss of BAF250a in benign endometriotic lesions. Interestingly, the stromal BAF250a expression was lower in ovarian endometriosis, as compared to eutopic endometrium, peritoneal endometriosis, and deep-infiltrating endometriosis \[[@B89-jpm-10-00041],[@B90-jpm-10-00041],[@B91-jpm-10-00041]\]. Identification of synthetic lethal targets that are conferred by these SWI/SNF-associated mutations on cancer cells requires further investigation and has important therapeutic potential. Targeting of sustained proliferative pathways, such as the PI3K/AKT/mTOR and the YES1/SRC tyrosine kinase pathways, or metabolic alterations, such as the glutathione biogenesis pathway, in *ARID1A*-deficient OCCC should be considered in future clinical trials. Such synthetic lethal agents in the *ARID1A* mutant setting are currently in clinical development. The inhibitory effects on residual SWI/SNF function, specifically via reduced ARID1B expression, may explain the enhanced sensitivity of *ARID1A* mutant cells to bromodomain and extraterminal domain (BET) inhibitors. As such, patients with *ARID1A* mutant OCCC may benefit from inhibitors of the BET family of proteins added to their treatment regimen.

The discovery of frequent somatic phosphatase and tensin homolog (*PTEN*) mutations and loss of heterozygosity at the 10q23 *PTEN* locus in EnOC, along with an absence of such mutations in other histological subtypes, suggests a key role for *PTEN* in the etiology of this subtype. Using a mouse model, Dinulescu et al. induced EnOC and saw that expression of oncogenic *KRAS* or conditional *PTEN* deletion within the ovarian surface epithelium forms endometriotic precursor lesions. These alterations led to the development of invasive EnOC \[[@B92-jpm-10-00041]\].

EZH2 is a histone methyltransferase that sets the H3K27me3 histone mark, a repressor of the transcriptional machinery. EZH2 also enhances angiogenesis, with a key role in ovarian carcinogenesis \[[@B93-jpm-10-00041]\]. Higher levels of EZH2 correlated to a worse prognosis for EOC patients \[[@B94-jpm-10-00041]\]. Due to in vivo-detected toxicity of first-generation EZH2 inhibitors, novel EZH2 inhibitors are currently investigated \[[@B95-jpm-10-00041]\]. The NRG-GY-014 phase II clinical trial assessing the EZH2-inhibitor tazemetostat in recurrent EnOC, OCCC, and/or recurrent low-grade endometrioid endometrial carcinoma is currently recruiting \[[@B96-jpm-10-00041]\].

There are several studies where differential expression of miRNAs has been studied in either endometriosis or ovarian cancer. Several differentially expressed miRNA in endometriosis compared to ovarian cancer have been found, mainly linked with epithelial--mesenchymal transition \[[@B97-jpm-10-00041]\]. Two common miRNAs overexpressed in both diseases were miR-325 and miR-492. While the expression of miR-325 was upregulated in both diseases, this was more prominent in ovarian cancer, suggesting that miR-325 could have a role in the transition from endometriosis to ovarian cancer \[[@B97-jpm-10-00041]\].

Among well-investigated epigenetic drugs in the field of ovarian cancer are histone deacetyltransferase (HDAC) inhibitors, which work by increasing the level of acetylated histones thus reactivating silenced tumor suppressor genes. Currently, only three HDAC inhibitors---vorinostat, romidepsin, and panobinostat---have been approved by the FDA \[[@B98-jpm-10-00041]\]. HDAC inhibitors seem to be effective particularly in combination with other anti-cancer drugs and/or radiotherapy. A combination of DNA methyltransferases (DNMTs) and HDAC inhibitors has been shown to overcome platinum resistance in ovarian cancer. It has been demonstrated that the DNMT inhibitor decitabine may lead to demethylation of many genes, including *BRCA1* \[[@B99-jpm-10-00041]\].

Hydralazine is a non-nucleoside DNA-demethylating drug with an anti-hypertensive effect. The mechanism of action of hydralazine is still a controversial issue, as some groups claimed that it binds to the catalytic site of DNMTs, while others reported that it reduces DNMT1 and DNMT3a expression via the extracellular signal-regulated kinase (ERK) pathway inhibition. This drug, combined with valproic acid, was assessed in refractory solid tumors, including ovarian cancer \[[@B100-jpm-10-00041]\].

Another combination approach with good response refers to epigenetic inhibitors and immunotherapy. In a mouse model of EOC, DNMT and HDAC inhibitors improved the response to immune checkpoint therapy. Specifically, the DNMT inhibitor 5-azacytidine increased the number of CD45+ immune cells and the percentage of natural killer cells and active CD8+ cells in the microenvironment. As a result, tumor burden was reduced and survival was prolonged. A triple combination therapy consisting of a DNMT, HDAC, and an immune checkpoint inhibitor provided the greatest efficacy \[[@B101-jpm-10-00041]\].

An overview of current clinical trials mainly regarding OCCC using an *ARID1A*-related treatment approach is available in [Table 4](#jpm-10-00041-t004){ref-type="table"}.

7. Management of Malignant Ovarian Germ Cell Tumors (MOGCTs) {#sec7-jpm-10-00041}
============================================================

Non-epithelial ovarian cancers are a group of uncommon, histologically, and clinically distinct tumors, with favorable prognosis as compared with the majority of their epithelial counterparts \[[@B102-jpm-10-00041]\]. The two most frequently diagnosed non-epithelial ovarian cancers are MOGCTs and SCSTs, with several histological subtypes \[[@B103-jpm-10-00041]\]. SCSTs arise from the sex cord and ovarian stroma and comprise granulosa cell tumors---the most common subtype, subdivided into juvenile and adult types---Sertoli--Leydig cell tumors, theca cell tumors and rare SCSTs with annular tubules. Ovarian small-cell cancers (hypercalcemic and non-hypercalcemic types) and sarcomas are extremely rare and aggressive cancers with dismal prognosis \[[@B27-jpm-10-00041],[@B104-jpm-10-00041]\].

MOGCTs account for only 2--5% of all ovarian cancers. They typically occur in children and young women aged 10--30 years, with a peak incidence in the teenage years \[[@B105-jpm-10-00041]\]. Their rarity in postmenopausal women can cause initial diagnostic uncertainty and lead to delayed or suboptimal treatment \[[@B106-jpm-10-00041]\]. MOGCTs are divided into dysgerminomas and non-dysgerminomas including primarily yolk sac tumors and immature teratomas. The presence of bilateral ovarian involvement suggests dysgerminoma or mixed histology, with a predominant dysgerminoma element. Signs and symptoms of MOGCTs usually include abdominal pain with a palpable pelvic abdominal mass (85%), followed by abdominal distension (35%), fever and vaginal bleeding (10% each). Those patients may also exhibit symptoms of pregnancy or precocious puberty, related to β-human chorionic gonadotropin production by the tumor. Adverse prognostic factors include advanced-stage, residual tumor after salvage surgery, non-dysgerminoma histology, as well as elevated Ca125 and age \> 40 years at initial diagnosis. Even advanced/metastatic disease is potentially curable, at least in 75% of cases \[[@B103-jpm-10-00041]\].

Surgical staging remains the cornerstone in the management of MOGTs. Surgical procedures include exploratory laparotomy, peritoneal washing, omental biopsy, unilateral oophorectomy, and selective removal of enlarged lymph nodes. Hysterectomy and bilateral salpingo-oophorectomy and can be considered in patients who do not wish to preserve fertility \[[@B107-jpm-10-00041]\]. This is not always feasible, given that MOGCTs typically affect women of childbearing age. Approximately 60--70% of MOGCTs are diagnosed at stage I. These tumors can be cured without postoperative chemotherapy. Fertility sparing surgery can be also proposed in advanced stages after careful discussion with young patients who desire pregnancy \[[@B108-jpm-10-00041]\]. In the case of residual teratoma, second-look surgery is therapeutically indicated \[[@B109-jpm-10-00041]\]. Current approaches to the treatment are summarized in [Table 5](#jpm-10-00041-t005){ref-type="table"}.

The bleomycin/etoposide/cisplatin (BEP) regimen is the preferred adjuvant chemotherapy. There is consensus that three cycles of BEP prevent recurrence in cases with completely resected disease. Four to five cycles are recommended for patients with macroscopic residual disease; nevertheless, this should be continued for up to six cycles in those with ongoing radiological or biochemical response \[[@B103-jpm-10-00041]\]. The ongoing chemotherapy phase 3 trials, summarized in [Table 6](#jpm-10-00041-t006){ref-type="table"}, may change the clinical management of MOGCTs. The long-term side effects of platinum-based chemotherapy for MOGCTs are mostly irreversible and the severity is related to the chemotherapy cumulative dose. Identification of patients more likely to experience cisplatin-related toxicities could be based on several single-nucleotide polymorphisms \[[@B110-jpm-10-00041]\].

Recurrences usually occur within two years of initial diagnosis and typically relapse peritoneal cavity and retroperitoneal lymph nodes. The salvage rate for chemotherapy in patients with MOGCTs is approximately 50%, and recommended regimens include vinblastine, ifosfamide, and cisplatin; etoposide, ifosfamide, and cisplatin; and paclitaxel, ifosfamide, and cisplatin \[[@B111-jpm-10-00041],[@B112-jpm-10-00041]\]. Secondary cytoreductive surgery could be performed in selected patients with recurrent disease.

Somatic mutations in MOGCTs are not a frequent phenomenon. The low mutation rate, the *p*53 wild-type signature, and other somatic copy number aberrations support the resemblance of MOGCTs to testicular germ cell tumors. An analysis of 87 MOGCTs identified recurrent mutations in *KIT* and *KRAS*, along with frequent focal amplifications of *PIK3CA* and *AKT1* in yolk sac tumors \[[@B113-jpm-10-00041]\]. However, the clinical efficacy of any targeted treatment has not been reported in unselected patient populations. The lack of efficacy of imatinib in MOGCTs is probably related to the frequent mutations in the KIT enzymatic site, which leads to reduced sensitivity to imatinib blockade \[[@B114-jpm-10-00041]\]. Further investigation of CDK4/6 inhibition for the treatment of teratoma is required based on the preliminary results indicating the safety and potential clinical benefit \[[@B115-jpm-10-00041]\]. Similarly, immune checkpoint inhibitors in MOGCTs need to be unraveled \[[@B115-jpm-10-00041],[@B116-jpm-10-00041]\].

8. Conclusions and Future Perspectives {#sec8-jpm-10-00041}
======================================

Since inflammatory and epigenetic processes play a predominant role in the pathogenesis of endometriosis-associated ovarian carcinomas, immunotherapy as well as epigenetic treatment approaches open the way to more personalized and adaptive therapies. A combination of multiple biomarker changes rather than a single gene or marker is involved in the initiation and progression of either disease. Genetic risk has an important impact on ovarian cancer. The evolution of NGS allows a rapid evaluation of multiple cancer susceptibility genes at similar costs to single gene sequencing. Germline genetic testing should be offered to all newly diagnosed patients with EOC to detect gPVs in all genes associated with EOC susceptibility. Furthermore, tumor sequencing to identify potentially targetable somatic mutations is increasingly being used in high-grade serous EOC and influences decisions on patient treatment. HR deficiency remains a strong predictor of clinical benefit from PARP inhibitors. Beyond germline, PARP inhibitors may be effective in somatic *BRCA1/2* mutations as well. Among other tumors, high-grade serous EOCs have shown a high frequency of phenotypes with a gain of function of *AURK* and a loss of function of *p53*. An understanding of the functional diversity of AURKs could help to evaluate their relevance as potential therapeutic targets. Anti-mitotic, anti-angiogenic, and anti-inflammatory effects of metformin are well studied in vitro. Ongoing clinical trials will potentially clarify the role of metformin in ovarian cancer treatment. MOGCTs are rare entities, treated with surgery and possibly platinum-based regimens based on the stage of the disease. Preclinical work on MOGCTs is warranted to allow investigation of novel drug targets.
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###### 

Impact of moderate- and high-penetrance genes for EOC.

  ------------------------------------------------------------------------------------------------------------------------------------
  Gene                                         Histologic Subtype   Frequency of Germline Pathogenic Variants   Lifetime Risk of EOC
  -------------------------------------------- -------------------- ------------------------------------------- ----------------------
  *BRCA1*                                      HGSOC                3--15%                                      39--63%

  *BRCA2*                                      3--6%                17--27%                                     

  *RAD51C*                                     0--2%                5.2--9%                                     

  *RAD51D*                                     0--1%                10--12%                                     

  *BRIP1*                                      0--2%                5.8%                                        

  MMR genes (*MLH1*, *MSH2*, *MSH6*, *PMS2*)   1\. Endometrioid;\   0--1%                                       4--12%
                                               2. Clear-cell                                                    
  ------------------------------------------------------------------------------------------------------------------------------------

EOC: epithelial ovarian cancer; HGSOC: high-grade serous ovarian cancer; MMR: mismatch repair.
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###### 

Clinical trials of EOC patients with homologous recombination (HR) deficiency.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                        Population                                                   Treatment Arms                     Median PFS                         HR     *p*
  ------------------------------------------------------------ ------------------------------------------------------------ ---------------------------------- ---------------------------------- ------ ----------
  SOLO-1                                                       Newly diagnosed stage III/IV high-grade EOC,\                Arm A: Olaparib\                   PFS rate at 3 y,\                  0.28   \<0.001
                                                               *BRCA1/2* mutated,\                                          Arm B: Placebo                     Arm A: 69%\                               
                                                               maintenance setting                                                                             Arm B: 35%                                

  SOLO-2                                                       Platinum-sensitive relapsed EOC,\                            Arm A: Olaparib\                   Arm A: 19.1 m\                     0.30   \<0.0001
                                                               *BRCA1/2* mutated,\                                          Arm B: Placebo                     Arm B: 5.5 m                              
                                                               maintenance setting                                                                                                                       

  SOLO-3                                                       Recurrent EOC,\                                              Arm A: Olaparib\                   Arm A: 13.4 m\                     0.62   0.013
                                                               g*BRCA*m                                                     Arm B: CTH of physician's choice   Arm B: 9.2 m                              

  NOVA                                                         Recurrent EOC,\                                              Arm A: Niraparib\                  g*BRCA*m cohort,\                  0.27   \<0.001
                                                               previous response to platinum-based CTH,\                    Arm B: Placebo                     Arm A: 21 m\                              
                                                               maintenance setting                                                                             Arm B: 5.5 m                              

  Non-g*BRCA*m cohort with HRD,\                               0.38                                                         \<0.001                                                                      
  Arm A: 12.9 m\                                                                                                                                                                                         
  Arm B: 3.8 m                                                                                                                                                                                           

  Overall non-g*BRCA*m cohort,\                                0.45                                                         \<0.001                                                                      
  Arm A: 9.3 m\                                                                                                                                                                                          
  Arm B: 3.9 m                                                                                                                                                                                           

  ARIEL 3                                                      Recurrent EOC,\                                              Arm A: Rucaparib\                  Patients with *BRCA* mutations,\   0.23   \<0.0001
                                                               previous response to platinum-based CTH,\                    Arm B: Placebo                     Arm A: 16.6 m\                            
                                                               maintenance setting                                                                             Arm B: 5.4 m                              

  Patients with HRD,\                                          0.32                                                         \<0.0001                                                                     
  Arm A: 13.6 m\                                                                                                                                                                                         
  Arm B: 5.4 m                                                                                                                                                                                           

  ITT population,\                                             0.36                                                         \<0.0001                                                                     
  Arm A: 10.8 m\                                                                                                                                                                                         
  Arm B: 5.4 m                                                                                                                                                                                           

  PAOLA 1                                                      Newly diagnosed stage III/IV high-grade EOC,\                Arm A: Bevacizumab + olaparib\     Overall population,\               0.59   \<0.001
                                                               *BRCA1/2* mutated,\                                          Arm B: Bevacizumab + placebo       Arm A: 22.1 m\                            
                                                               responders to first line platinum-taxane CTH + bevacizumab                                      Arm B: 16.6 m                             

  Patients with HRD, including those with *BRCA* mutations,\   0.33                                                                                                                                      
  Arm A: 37.2 m\                                                                                                                                                                                         
  Arm B: 17.7 m                                                                                                                                                                                          

  Patients with HRD, without *BRCA* mutations,\                0.43                                                                                                                                      
  Arm A: 28.1 m\                                                                                                                                                                                         
  Arm B: 16.6 m                                                                                                                                                                                          
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

EOC: epithelial ovarian cancer; PFS: progression-free survival; y: year; m: month; CTH: chemotherapy; HRD: homologous recombination deficiency; HR: hazard ratio; ITT: intention to treat population.
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###### 

Incidence of ovarian cancer in metformin users among women with type 2 diabetes.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Publication Reference     Design                       Cancer Patients (*n*)   Ovarian Cancer Patients (*n*)   Metformin Users (*n*)   Reference Group                             Outcome
  ------------------------- ---------------------------- ----------------------- ------------------------------- ----------------------- ------------------------------------------- -------------------------------------------------------------------
  \[[@B79-jpm-10-00041]\]   Case-control analysis        1611                    85                              41                      Women with T2D and no prior metformin use   OR 0.38 (95% CI 0.18--0.81) when ≥10 prescriptions of metformin;\
                                                                                                                                                                                     OR 0.59 (95% CI 0.25--1.41) when \<10 prescriptions of metformin

  \[[@B80-jpm-10-00041]\]   Observational study          479,475                 3201                            601                     Women with T2D and no use of metformin      aHR 0.66 (95% CI 0.59--0.73);\
                                                                                                                                                                                     *p* \< 0.01

  \[[@B81-jpm-10-00041]\]   Retrospective cohort study   NA                      303                             303                     Women with T2D using other oral ADM         Full cohort aHR 1.02 (95% CI 0.72--1.45);\
                                                                                                                                                                                     Case-control aHR 0.91 (95% CI 0.61--1.34)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OR: odds ratio; CI: confidence interval; aHR: adjusted hazard ratio; ADM: anti-diabetic medication.
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###### 

Clinical trials in gynecological cancer using an *ARID1A*-related treatment approach ([www.clinicaltrials.gov](www.clinicaltrials.gov)).

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study/Status               Phase   Patients *n*   Agent                                                                      Design                                                                                                                                                                                                                                      Primary Outcome
  -------------------------- ------- -------------- -------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------
  NCT04065269/Recruiting     II      40             AZD6738 (ATR inhibitor) + olaparib                                         Experiment 1A: AZD6738;\                                                                                                                                                                                                                    ORR
                                                                                                                               relapsed ovarian (fallopian tube/primary peritoneal) and endometrial clear cell carcinomas with loss of *ARID1A* expression\                                                                                                                
                                                                                                                               Experiment 1B: AZD6738 + olaparib;\                                                                                                                                                                                                         
                                                                                                                               (depending on response rate in cohort 1A);\                                                                                                                                                                                                 
                                                                                                                               relapsed ovarian (fallopian tube/primary peritoneal) and endometrial clear cell carcinomas with loss of *ARID1A* expression\                                                                                                                
                                                                                                                               Experiment 2: AZD6738 + olaparib;\                                                                                                                                                                                                          
                                                                                                                               relapsed ovarian (fallopian tube/primary peritoneal) and endometrial clear cell carcinomas without loss of *ARID1A* expression\                                                                                                             
                                                                                                                               Experiment 3: AZD6738 + olaparib;\                                                                                                                                                                                                          
                                                                                                                               relapsed rare gynecological cancers (endometrioid ovarian carcinoma, endometrioid endometrial carcinoma, cervical adenocarcinoma, cervical squamous, ovarian carcinosarcoma and endometrial carcinosarcoma) regardless of *ARID1A* status   

  NCT02059265/Active, not\   II      35             Dasatinib                                                                  Dasatinib OD, days 1--28, until PD or unacceptable toxicity;\                                                                                                                                                                               ORR
  recruiting                                                                                                                   endometrial clear cell adenocarcinoma;\                                                                                                                                                                                                     
                                                                                                                               ovarian clear cell cystadenocarcinoma;\                                                                                                                                                                                                     
                                                                                                                               recurrent fallopian tube carcinoma;\                                                                                                                                                                                                        
                                                                                                                               recurrent ovarian carcinoma;\                                                                                                                                                                                                               
                                                                                                                               recurrent primary peritoneal carcinoma;\                                                                                                                                                                                                    
                                                                                                                               recurrent uterine corpus carcinoma;                                                                                                                                                                                                         

  NCT03297424/Recruiting     I/II    166            PLX2853 (BRD4 inhibitor)                                                   phase 1b (dose escalation):\                                                                                                                                                                                                                1\. AEs;\
                                                                                                                               up to 30 subjects with advanced malignancies\                                                                                                                                                                                               2. Pharmacokinetics of PLX2853 (AUC, Cmax, Tmax, t1/2);\
                                                                                                                               phase 2a (dose expansion):\                                                                                                                                                                                                                 3. Dose-limiting toxicity;\
                                                                                                                               5 expansion cohorts in total;\                                                                                                                                                                                                              4. Response by RECIST 1.1 (solid tumors) or Lugano criteria (NHL)
                                                                                                                               expansion cohorts 1--4: either 10 or 29 subjects per cohort: advanced SCLC, uveal melanoma, OCCC, and any other advanced malignancy with a known *ARID1A* mutation;\                                                                        
                                                                                                                               expansion cohort 5: up to 20 subjects may be enrolled for NHL                                                                                                                                                                               

  NCT03348631/Suspended      II      86             Tazemetostat (EZH2 inhibitor)                                              Tazemetostat BID, days 1--28, until PD or unacceptable toxicity;\                                                                                                                                                                           ORR
                                                                                                                               FIGO grade 1/2 endometrial endometrioid; adenocarcinoma;\                                                                                                                                                                                   
                                                                                                                               recurrent endometrial endometrioid; adenocarcinoma;\                                                                                                                                                                                        
                                                                                                                               recurrent ovarian carcinoma;\                                                                                                                                                                                                               
                                                                                                                               recurrent ovarian clear cell adenocarcinoma;\                                                                                                                                                                                               
                                                                                                                               recurrent ovarian endometrioid; adenocarcinoma;\                                                                                                                                                                                            
                                                                                                                               recurrent uterine corpus carcinoma                                                                                                                                                                                                          

  NCT01914510/Completed      II      40             ENMD-2076 (oral anti-angiogenic and anti-proliferative kinase inhibitor)   ENMD-2067 275 mg, OD, days 1--28;\                                                                                                                                                                                                          1\. 6 month PFS rate;\
                                                                                                                               starting dose of 250 mg, OD, days 1--28 in subjects with a body surface area of less than 1.65 m^2^                                                                                                                                         2. CR rate;\
                                                                                                                                                                                                                                                                                                                                                                           3. PR rate
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ATR: ataxia telangiectasia and Rad3-related kinase; ORR: overall response rate; OD: once a day; PD: progressive disease; BRD4: bromodomain-containing protein 4; SCLC: small-cell lung cancer; OCCC: ovarian clear cell carcinoma; NHL: non-Hodgkin lymphoma; AEs: adverse events; AUC: area under the concentration--time curve; Cmax: maximum observed concentration; Tmax: time to peak concentration; t1/2: half-life; RECIST: Response Evaluation Criteria in Solid Tumors; EZH2: enhancer of zeste homolog 2; BID: twice a day; FIGO: International Federation of Gynecology and Obstetrics; PFS: progression-free survival; CR: complete response; PR: partial response.
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###### 

Management options for malignant ovarian germ cell tumors (MOGCTs).

  -------------------------------------------------------------------------------------------------------------------------------------
                             Dysgerminomas                                                                 Immature Teratomas   Other
  -------------------------- ----------------------------------------------------------------------------- -------------------- -------
  Stage I                    USO with preservation of the contralateral ovary and uterus for fertility;\                        
                             TAH-BSO is acceptable if childbearing has been completed                                           

  Stage IA                   No ACT                                                                        G1: No ACT           ACT

  G2: Consideration of ACT                                                                                                      

  G3: ACT                                                                                                                       

  Stage IB/C                 ACT                                                                                                

  Stage II                   USO with preservation of the contralateral ovary and uterus for fertility;\                        
                             TAH-BSO is acceptable if childbearing has been completed;\                                         
                             ACT                                                                                                

  Stage III/IV               USO with preservation of the contralateral ovary and uterus for fertility;\                        
                             TAH-BSO is acceptable if childbearing has been completed;\                                         
                             UDS-ACT;\                                                                                          
                             NACT-IDS when indicated                                                                            

  Recurrent tumors           Palliative chemotherapy                                                                            
  -------------------------------------------------------------------------------------------------------------------------------------

MOGCTs: malignant ovarian germ cell tumors; USO: unilateral salpingo-oophorectomy; TAH-BSO: total abdominal hysterectomy and bilateral salpingo-oophorectomy; ACT: adjuvant chemotherapy; G: grade; UDS: upfront debulking surgery; NACT: neoadjuvant chemotherapy; IDS: interval debulking surgery.
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###### 

Phase III trials of combination chemotherapy in MOGCTs still recruiting patients.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                      Population                                                          Patients *n*   Treatment Arms                                       Primary Endpoint
  -------------------------- ------------------------------------------------------------------- -------------- ---------------------------------------------------- ----------------------------------------------------------
  TIGER (NCT02375204)        Relapsed or refractory disease                                      420            Arm A:\                                              OS
                                                                                                                CDCT (TIP)\                                          
                                                                                                                Arm B:\                                              
                                                                                                                HDCT plus ASCT with TI-CE                            

  MOGCT-01 (NCT02429687)     Stage IIA-IVB,\                                                     129            Arm A:\                                              PFS
                             adjuvant treatment                                                                 PT\                                                  
                                                                                                                Arm B:\                                              
                                                                                                                BEP                                                  

  ANZUP-1302 (NCT02582697)   Stage IV,\                                                          500            Arm A:\                                              PFS
                             intermediate or poor prognosis as defined by IGCCC classification                  accelerated BEP\                                     
                                                                                                                Arm B:\                                              
                                                                                                                standard BEP                                         

  NCT03067181                Low-risk stratum:\                                                  1680           Arm A:\                                              1\. OS;\
                             *Age (years)*:\                                                                    bleomycin/carboplatin/etoposide (up to 4 cycles)\    2. PFS
                             \<50 years;\                                                                       Arm B:\                                              
                             *Sites*:\                                                                          BEP (up to 4 cycles)\                                
                             ovarian immature teratoma, GCT (all sites);\                                       Arm C:\                                              
                             *Stage*:\                                                                          bleomycin/carboplatin/etoposide (up to 3 cycles)\    
                             Stage I\                                                                           Arm D:\                                              
                             Standard risk 1:\                                                                  BEP (up to 3 cycles)\                                
                             *Age (years)*:\                                                                    Experiment (low risk):\                              
                             \<11;\                                                                             observation                                          
                             *Sites*:\                                                                                                                               
                             ovarian, testicular, or extragonadal site;\                                                                                             
                             *Stage*:\                                                                                                                               
                             FIGO stage II-IV; YST, EC, or choriocarcinoma\                                                                                          
                             Standard risk 2:\                                                                                                                       
                             *Age (years)*:\                                                                                                                         
                             \>= 11 and \<25;\                                                                                                                       
                             *Ovarian*:\                                                                                                                             
                             FIGO stage IC, II/III;\                                                                                                                 
                             YST, EC, or choriocarcinoma;\                                                                                                           
                             *Testicular*:\                                                                                                                          
                             AJCC stage II/III, IGCCC good risk;\                                                                                                    
                             YST, EC, or choriocarcinoma;\                                                                                                           
                             *Extragonadal*:\                                                                                                                        
                             COG stage II;\                                                                                                                          
                             YST, EC, or choriocarcinoma                                                                                                             

  NCT03418844                MOGCTs\                                                             480            Self-questionnaires of living conditions and QoL;\   1\. Chronic fatigue;\
                             SCSTs\                                                                             Interest group:\                                     2. Late sequelae of CTH (cardiac, pulmonary disorders);\
                             Remission \> 2 years following initial treatment                                   patients treated with chemotherapy\                  3. QoL
                                                                                                                Control group:\                                      
                                                                                                                patients not treated with chemotherapy               
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MOGCTs: malignant ovarian germ cell tumors; CDCT: conventional-dose chemotherapy; TIP: paclitaxel/ifosfamide/cisplatin; HDCT: high-dose chemotherapy; ASCT: autologous stem cell transplant; TI-CE: paclitaxel plus ifosfamide followed by high-dose carboplatin and etoposide; OS: overall survival; PT: paclitaxel/cisplatin; BEP: bleomycin/etoposide/cisplatin; PFS: progression-free survival; IGCCC: international germ cell cancer consensus classification; GCT: germ cell tumors; FIGO: International Federation of Gynecology and Obstetrics; YST: yolk sac tumor; EC: embryonal carcinoma; AJCC: American Joint Committee on Cancer; COG: Children's Oncology Group; SCSTs: sex cord-stromal cell tumors; QoL: quality of life; CTH: chemotherapy.
